Here’s a practical, end-to-end view of how licensing a compound from a large pharma company typically works. The exact path varies by asset stage, therapeutic area, geography, and the negotiating leverage of the parties, but the core flow is usually similar.
1) Strategic fit and initial outreach
- Define what you’re looking for: indication, patient population, modality (small molecule, biologic), stage (preclinical, Phase I/II/III).
- Do market and competitive landscape mapping.
- The pharma company’s business development (BD) group receives inquiries, often via an intermediary (investment bank, BD advisor) or directly.
- Non-disclosure agreement (NDA) is signed to share confidential data.
2) Confidential data review and early screening
- Access to a data room with known data: preclinical/clinical data, CMC (chemistry, manufacturing, controls), IP landscape, safety signals, regulatory status.
- Your team screens for scientific/clinical viability, strategic fit, and IP freedom-to-operate.
- Internal alignment: ensure senior management backing and budget for potential deal.
3) Expression of interest and initial term concepts
- If you’re interested, you may issue an LOI/term-sheet outline or request a more formal term sheet.
- Early questions to define: exclusivity (global vs. field-limited), upfront payment expectations, milestone and royalty framework, development responsibilities, manufacturing and supply rights, and who bears which costs.
4) Non-binding term sheet or LOI
- A non-binding document covers key deal terms: scope of license (territory, field), exclusivity, upfront payment (if any), milestones, royalties, development responsibilities, data/material transfer, IP ownership and improvements, sublicensing, and post-termination rights.
- Often includes a short exclusivity period (time to complete diligence and negotiate definitive agreements).
5) Due diligence (scientific, regulatory, commercial, IP)
- Scientific and clinical data review: validity of efficacy signals, safety signals, and regulatory strategy.
- IP due diligence: freedom-to-operate, strength of composition-of-matter claims, method-of-use claims, patent life, ownership, and freedom to sublicense.
- Commercial due diligence: market size, competition, pricing, reimbursement landscape, and potential partnerships or co-development options.
- Legal/compliance checks: antitrust/regulatory considerations, export controls, anti-corruption (FCPA/UK Bribery Act) implications.
6) Deal structuring and negotiation
- License scope: exclusive vs. non-exclusive; field-limited; geography-limited; if needed, regional licenses.
- Economics:
- Upfront payment: paid on signing (often modest for early-stage assets, higher for late-stage assets).
- Milestones: development (e.g., IND/CMC, Phase milestones), regulatory milestones (BLA/MAA submission, approval), commercial milestones (launch, peak sales).
- Royalties: tiered rates, often a percentage of net sales, with higher rates in certain territories or indications; may be structured as percentages or caps.
- Cost sharing: development costs, post-approval commercialization costs, or allocations for certain studies.
- Sublicensing and transfer pricing, if applicable.
- Development and governance: joint development committees, decision rights, milestones’ timing, and what happens if a milestone is missed.
- Regulatory responsibilities: which party leads IND/CTA submissions, Phase 3 trials, regulatory filings, pharmacovigilance obligations.
- Manufacturing and supply: who controls CMC, sourcing, scale-up, and capacity commitments.
- IP and data: ownership of foreground IP (developed improvements), background IP usage rights, confidentiality, data sharing, and publication rights.
- Post-termination rights: wind-down period, transitional supply, data access, and “evergreen” rights for ongoing trials.
- Representations, warranties, and indemnities: ownership of IP, non-infringement, regulatory compliance, animal/human data integrity, etc.
- Compliance and ethics: anti-bribery, conflicts of interest, and audit rights.
- Drafting of definitive agreements: license agreement, material transfer agreements, supply agreements, and any side letters.
7) Definitive agreements and closing
- A binding license agreement (and related documents) is executed.
- Financials are settled (upfront paid; milestones and royalties to be tracked).
- Transfer of know-how, data, and any necessary materials; transfer of manufacturing information if applicable.
- Regulatory and compliance steps completed; anti-trust clearances if required.
8) Post-close program management
- Ongoing program governance (often via a joint steering committee).
- Milestone tracking and reporting; royalty accounting and audits.
- Update of development plans, potential mid-course amendments based on emerging data.
- Sublicensing management and ongoing IP strategy.
Key terms and what tends to move the needle
- Exclusivity and field: more exclusivity = higher upfront and tighter milestones.
- Stage of asset: late-stage assets typically command larger upfronts and higher milestones; early-stage assets rely more on milestones and royalties.
- IP strength: strong, broad, enforceable composition-of-matter and method-of-use claims reduce uncertainty.
- Data access: who gets access to safety data, IND/CTD packages, and CMC documents; data room depth matters.
- Development cost sharing: who funds later-stage trials and pivotal studies; impact on economics.
- Post-approval economics: whether the licensee pays royalties on net sales after approval and how they scale with sales.
Typical timelines (rough guide)
- Initial outreach to NDA: 1–3 weeks for NDA exchange and data room setup.
- LOI/term sheet to signature of definitive agreement: 1–4 months (often longer for late-stage assets; 6–12 months is common for complex deals).
- Due diligence: 4–8 weeks (could be longer for complex IP and regulatory questions).
- Definitive agreement to closing: 1–3 months, after all regulatory and internal approvals.
- Overall process: roughly 3–12 months, depending on asset complexity, the negotiating power of the parties, and regulatory/antitrust clears.
What to prepare if you’re the licensee (buyer)
- A well-constructed target product profile and development plan.
- A due diligence checklist for IP, regulatory status, safety signals, and manufacturing feasibility.
- Financial model: best-case/worst-case scenarios, milestone payoff timing, and royalty waterfall.
- A plan for regulatory strategy, including which regions you’ll pursue first.
- A list of potential risk mitigations (patent challenges, toxicity signals, supply chain issues).
What to prepare if you’re the licensor (large pharma)
- Clear articulation of the scope of the license (territory, fields, exclusivity).
- A data room with curated, up-to-date scientific and regulatory information.
- A preferred deal template and readiness to share a non-binding term sheet quickly to maintain momentum.
- IP landscape and freedom-to-operate analysis.
- Internal approvals and budgetary thresholds.
If you’d like, tell me:
- the asset stage (discovery, preclinical, Phase I/II/III),
- target indications and geography of interest,
- whether you want exclusive or non-exclusive rights, and
- rough budget or upfront/milestone expectations.
I can tailor a more specific, step-by-step plan, a term-sheet outline, and a checklist for your situation.